Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares MEK1/2, BRAF, Ipilimumab, RAS / RAF / MEK / ERK (MAPK) and the tag subtype-page.
Shares Binimetinib, MEK1/2, Encorafenib, BRAF and the tag subtype-page.
Shares MEK1/2, Ipilimumab, RAS / RAF / MEK / ERK (MAPK), Nivolumab and the tag subtype-page.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Nivolumab, PD-1 and the tag subtype-page.
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Ipilimumab, Liquid biopsy (ctDNA), Nivolumab and the tag subtype-page.
Shares CAPOX (capecitabine, oxaliplatin), FOLFOX (5-FU, leucovorin, oxaliplatin), Nivolumab, Pembrolizumab and the tag subtype-page.
Shares CAPOX (capecitabine, oxaliplatin), FOLFOX (5-FU, leucovorin, oxaliplatin), Nivolumab, Pembrolizumab and the tag subtype-page.
Shares Cetuximab, EGFR, PD-1, Pembrolizumab and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.